As of today, Numedicus is instantiating a Twitter feed of new drug repurposing opportunities…see http://twitter.com/numedicus
This week’s announcement from Boehringer Ingelheim that it is acquiring, after entry into clinical trials, the key asset of FX125L from Funxional Therapeutics, may perhaps change the language of pharmaceutical discovery.
The drug regulatory system is directed towards the approval of new medicines for particular uses, based on clinical trials and other evidence that the product is effective and safe. Yet, once approved, it is in most jurisdictions possible for a doctor to prescribe the product for whatever use s/he sees fit. This is in accordance […]
I have dealt in the past with an analysis of the decline in patent-based drug exclusivity, pointing out that data exclusivity is becoming increasingly important. However, the time has come to raise the issue more broadly: the case for longer terms of commercial protection, in the interests of better medicines should be heard.
The recent news from Biogen-Idec of the success of their experimental drug BG-12 for relapsing-remitting multiple sclerosis is in many ways remarkable. Although BG-12 is not approved yet, here are seven things about it which challenge many of the widely held beliefs about how we should best discover drugs today.
Bruce Booth, who writes an informative and insightful blog about early stage life science venture capital, posts regularly about trends within the biotech industry, and recently about expectations for 2012. It seems the primary theme from this year’s Annual J.P. Morgan conference is innovation. Before going further, this requires some analysis. Innovation, a.k.a. Novelty, means […]
Last week David Cameron, the British Prime minister, announced a new policy to make available the data from National Health Service prescriptions in order to promote better new medicines discovery. I wonder if he had read an article published in Drug Discovery Today and available online from October 2011, wherein we say essentially the same […]
On 7th December 2010, we saw the release of important clinical information supporting the benefit of aspirin in preventing colorectal and other cancers. Truly, aspirin is a charmed drug. One of the oldest known therapeutics, this is now the third substantial therapeutic effect of the compound: first pain, then cardiovascular disease (stroke, myocardial infarction) and […]
Behind the headline of universal healthcare resulting from the recent Obama administration reforms, lies the simultaneous change to the regulation of biologic drugs imposed by the new legislation. The change concerns the data exclusivity period and process for follow-on biologic approval by the FDA. The Approval Pathway For Biosimilar Biological Products, provides clarity on an […]